IVB102注射液在X连锁视网膜劈裂受试者中的安全性和有效性研究
一项开放标签、剂量递增的临床研究,旨在评估 X 连锁视网膜劈裂 (XLRS) 受试者注射 IVB102 的安全性、耐受性和初步疗效
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.
研究概览
详细说明
This is a open label, dose escalation, single-center study. One eye of each participant will receive a single IVB102 injection by intravitreal injection. Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment.
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100142
- Peking Union Medical College Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Must be willing and able to provide written, signed informed consent.
- Male individual at least 8 years of age with clinical diagnosis of XLRS caused by mutations in RS1.
- Best corrected visual acuity (BCVA) in the study eye of less than or equal to 63 (corresponding to a Snellen acuity of 20/63).
- Must agree to use effective barrier (male or female condom) of contraception before dosing and continuing one year after gene transfer.
Exclusion Criteria:
- Lens, cornea, or other media opacities in the study eye that preclude adequate visualization and testing of the retina.
- Pre-existing eye conditions that would contribute significantly to visual loss or increase the risk of an intravitreal injection (e.g. DR、RVO or large retinal detachment).
- Any intraocular surgery in the study eye within 6 months prior to screening.
- Use of topical carbonic anhydrase inhibitors within 3 months prior to screening.
- Use of anticoagulants or anti-platelet agents within 7 days prior to study agent administration.
- Prior receipt of any AAV gene therapy product.
- Use of any investigational agent within 3 months prior to screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:IVB102 Treatment Arm(Low dose)
Intraocular injection of a single low dose of IVB102 |
Gene transfer by intravitreal injection of the RS1 AAV vector |
|
实验性的:IVB102 Treatment Arm(Intermediate dose)
Intraocular injection of a single intermediate dose of IVB102 |
Gene transfer by intravitreal injection of the RS1 AAV vector |
|
实验性的:IVB102 Treatment Arm(High dose)
Intraocular injection of a single high dose of IVB102 |
Gene transfer by intravitreal injection of the RS1 AAV vector |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of DLTs
大体时间:4 weeks
|
Number and proportion of dose limited toxicity(DLTs) |
4 weeks
|
|
Incidence of AEs
大体时间:52 weeks
|
Number and severity of overall and ocular Adverse Events (AEs) |
52 weeks
|
|
Incidence of SAEs
大体时间:52 weeks
|
Number and severity of overall and ocular Serious Adverse Events (SAEs) |
52 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual function
大体时间:52 weeks
|
Change from baseline in BCVA(Best Corrected Visual Acuity)(ETDRS) |
52 weeks
|
|
OCT imaging
大体时间:52 weeks
|
Change from baseline in CST(Central Retinal Thickness)(OCT) |
52 weeks
|
|
ERG parameters
大体时间:52 weeks
|
Change from baseline in response amplitudes measured using Electroretinogram (ERG) |
52 weeks
|
合作者和调查者
出版物和有用的链接
一般刊物
- Pimenides D, George ND, Yates JR, Bradshaw K, Roberts SA, Moore AT, Trump D. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005 Jun;42(6):e35. doi: 10.1136/jmg.2004.029769.
- Wang XF, Chen FF, Zhou X, Cheng XX, Xie ZG. A novel mutation in RS1 and clinical manifestations in a Chinese twin family with congenital retinoschisis. Front Genet. 2022 Sep 23;13:993157. doi: 10.3389/fgene.2022.993157. eCollection 2022.
- Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007 Apr;44(4):225-32. doi: 10.1136/jmg.2006.047340. Epub 2006 Dec 15.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.